Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-E9) – Biotin

SARS-CoV-2 Nucleocapsid (N) Protein

This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.

Ships Overnight on Blue Ice

Anti-SARS-CoV-2 Nucleocapsid, clone NP1-E9, specifically targets an epitope on the SARS-CoV-2 nucleocapsid protein. Futhermore, it is reported to bind to the oligomerization domain of the N protein.

The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family ¹. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) ². The N protein is 46 kDa and consists of two highly conserved structural domains, the N-terminal domain (NTD) and C-terminal domain (CTD), connected by a linker region. The NTD and CTD are involved in RNA binding and self-oligomerization, respectively ^{3, 4}. The primary function of the N protein is to bind to and package the viral RNA genome into a helical ribonucleoprotein complex ⁵. The N protein is also involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways ^{6, 7}. The N protein is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARS-CoV N protein ⁸. It is also immunogenic, and antibodies ^8,9 and memory T cells ^{10, 11} targeting the N protein are present in the sera of convalescent COVID-19 patients, identifying the N protein as a suitable candidate for vaccine development and diagnostic assays. Diagnostic assays based on the N protein effectively detect antibodies in the sera of patients infected with SARS-CoV-2 ¹². The N protein also contributes to immune evasion by antagonizing antiviral RNAi ¹³, suggesting its potential value as a targeted therapeutic.

1. Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270–273. 2020.
2. Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265–269. 2020.
3. Kang S, Yang M, Hong Z, et al. Acta Pharm Sin B. 10.1016/j.apsb.2020.04.009. 2020.
4. Chang CK, Sue SC, Yu TH, et al. J Biomed Sci. 13(1):59-72. 2006.
5. Hsieh PK, Chang SC, Huang CC, et al. J Virol. 79(22):13848-13855. 2005.
6. Surjit M, Lal SK. Infect Genet Evol. 8(4):397-405. 2008.
7. Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. J Virol. 84(19):10276-10288. 2010.
8. Guo L., Ren L., Yang S., et al. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020.
9. To K.K., Tsang O.T., Leung W.S., et al. Lancet Infect. Dis. 2020.
11. Ni L, Ye F, Cheng ML, et al. Immunity. 52(6):971-977.e3. 2020.
12. Liu L, Liu W, Zheng Y, et al. Microbes Infect. 22(4-5):206-211. 2020.
13. Mu J, Xu J, Zhang L, et al. Sci China Life Sci. 1-4. 2020.